GGrantIndex
← Leaderboards

Rajagopal Ramesh

University Of Oklahoma Hlth Sciences Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$13,394,577
Attributed
$14,304,734
Total exposure
16
Grants
16
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$14,304,734 · 14
VA$0 · 2

By mechanism

R01$9,932,643 · 6
P20$1,769,341 · 2
R25$1,551,435 · 2
P30$878,065 · 3
R03$173,250 · 1
I01$0 · 1

Top collaborators

Most similar at University Of Oklahoma Hlth Sciences Ctr

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo”

Research focus

In VivoMalignant NeoplasmsNeoplasm MetastasisIn VitroMolecularTumorMalignant Neoplasm Of LungCancer TherapyNeoplastic CellCellsResearch PersonnelBaseDiagnosisInnovationTumor XenograftLung NeoplasmsNanoparticlePreclinical StudyTumor GrowthLaboratoriesCancer CellNovel TherapeuticsSiteReporting

Grant awards (53)

Exosomes as carriers of cancer therapeutics$1,002,901
R01 · FY2025 · CA · contact PI
Engineered Nanoformulation for Immune-modulation in Cancer$564,843
R01 · FY2025 · CA · contact PI
Cell and Molecular Imaging Core$230,230
P30 · FY2025 · GM · contact PI
Cancer Undergraduate Research Experience (CURE) in Oklahoma$211,628
R25 · FY2025 · CA · contact PI
Cancer Research Training and Education Coordination$135,541
P30 · FY2025 · CA · contact PI
Native American Youths Enjoy Science - YES Oklahoma$134,319
R25 · FY2025 · CA · contact PI
Exosomes as carriers of cancer therapeutics$551,771
R01 · FY2024 · CA · contact PI
Engineered Nanoformulation for Immune-modulation in Cancer$535,400
R01 · FY2024 · CA · contact PI
Native American Youths Enjoy Science - YES Oklahoma$398,853
R25 · FY2024 · CA · contact PI
Cell and Molecular Imaging Core$230,230
P30 · FY2024 · GM · contact PI
Cancer Research Training and Education Coordination$141,033
P30 · FY2024 · CA · contact PI
Engineered Nanoformulation for Immune-modulation in Cancer$543,107
R01 · FY2023 · CA · contact PI
Native American Youths Enjoy Science - YES Oklahoma$399,160
R25 · FY2023 · CA
An improved IL-24 gene-based therapeutic for cancer$343,921
R01 · FY2023 · CA · contact PI
Exosomes as carriers of cancer therapeutics$144,805
R01 · FY2023 · CA · contact PI
Cancer Research Training and Education Coordination$141,031
P30 · FY2023 · CA · contact PI
Exosomes as carriers of cancer therapeutics$551,888
R01 · FY2022 · CA · contact PI
Native American Youths Enjoy Science - YES Oklahoma$407,475
R25 · FY2022 · CA
An improved IL-24 gene-based therapeutic for cancer$343,921
R01 · FY2022 · CA · contact PI
Small Animal Imaging Core$131,519
P20 · FY2022 · GM · contact PI
Exosomes as carriers of cancer therapeutics$576,222
R01 · FY2021 · CA · contact PI
An improved IL-24 gene-based therapeutic for cancer$350,939
R01 · FY2021 · CA · contact PI
Small Animal Imaging Core$146,128
P20 · FY2021 · GM · contact PI
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance$0
I01 · FY2021 · VA · contact PI
An improved IL-24 gene-based therapeutic for cancer$306,308
R01 · FY2020 · CA · contact PI
Small Animal Imaging Core$145,000
P20 · FY2020 · GM · contact PI
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance$0
I01 · FY2020 · VA · contact PI
An improved IL-24 gene-based therapeutic for cancer$317,518
R01 · FY2019 · CA · contact PI
Small Animal Imaging Core$145,000
P20 · FY2019 · GM · contact PI
ShEEP Request for CytoViva 3D Darkfield Hyperspectral Microscope$0
IS1 · FY2019 · VA · contact PI
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance$0
I01 · FY2019 · VA · contact PI
Small Animal Imaging Core$145,000
P20 · FY2018 · GM · contact PI
HuR Targeted Nanotherapy for Lung Cancer$342,194
R01 · FY2017 · CA · contact PI
Molecular Impact of Platinum Drugs on the Proteasome and SQSTM1_P62 Complexes_A Paradigm Shift in Resistance$0
I01 · FY2017 · VA · contact PI
HuR Targeted Nanotherapy for Lung Cancer$380,217
R01 · FY2016 · CA · contact PI
Small Animal Imaging Module$202,384
P20 · FY2016 · GM · contact PI
HuR Targeted Nanotherapy for Lung Cancer$380,217
R01 · FY2015 · CA · contact PI
Small Animal Imaging Module$207,492
P20 · FY2015 · GM · contact PI
HuR Targeted Nanotherapy for Lung Cancer$366,314
R01 · FY2014 · CA · contact PI
Small Animal Imaging Module$212,451
P20 · FY2014 · GM · contact PI
HuR Targeted Nanotherapy for Lung Cancer$402,385
R01 · FY2013 · CA · contact PI
Small Animal Imaging Module$208,035
P20 · FY2013 · GM · contact PI
Small Animal Imaging Module$226,332
P20 · FY2012 · GM · contact PI
Systemic Non-Viral Gene Therapy for Cancer$283,919
R01 · FY2011 · CA · contact PI
Systemic Non-Viral Gene Therapy for Cancer$319,550
R01 · FY2010 · CA · contact PI
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano$76,230
R03 · FY2010 · EB · contact PI
Systemic Non-Viral Gene Therapy for Cancer$319,550
R01 · FY2009 · CA · contact PI
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano$77,000
R03 · FY2009 · EB · contact PI
Preclinical Development and Testing of Multifunctional Tumor-Targeted Hybrid Nano$20,020
R03 · FY2009 · EB · contact PI
Systemic Non-Viral Gene Therapy for Cancer$319,550
R01 · FY2008 · CA · contact PI
Evaluate the antiangiogenic properties of mda-7/IL-24$217,771
R01 · FY2006 · CA · contact PI
Evaluate the antiangiogenic properties of mda-7/IL-24$228,190
R01 · FY2005 · CA
Evaluate the antiangiogenic properties of mda-7/IL-24$239,242
R01 · FY2004 · CA